Physician profile
Yuko Kono
NPI 1982628665
$15,664.78
in general payments reported to CMS, 2019-2025
18 companies · $3,319 in 2025
The $3,319 reported for 2025 was more than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,813 · 2020: $34.64 · 2022: $214 · 2023: $3,525 · 2024: $759 · 2025: $3,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,686 · Food and Beverage: $1,917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,686.00 |
| Food and Beverage | $1,916.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $4,771.34 | 2019 | |
| Lantheus Medical Imaging, INC. | $3,222.69 | 2023-2024 | Definity |
| Canon Medical Systems USA, INC. | $2,916.59 | 2019 | |
| Ge Healthcare | $2,750.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $557.45 | 2023-2025 | Imfinzi, Imjudo |
| Gilead Sciences, INC. | $389.70 | 2019-2025 | |
| Bracco Diagnostics INC. | $191.81 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.31 | 2020-2024 | Xifaxan |
| Boston Scientific Corporation | $155.37 | 2020-2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Madrigal Pharmaceuticals | $141.75 | 2025 | Rezdiffra |
| Fujifilm Healthcare Americas Corporation | $113.64 | 2023-2024 | Utaswako Afp-L3 |
| Eisai INC. | $109.33 | 2023-2025 | |
| Biocompatibles, INC. | $68.18 | 2019 | |
| Intercept Pharmaceuticals, INC. | $38.75 | 2023 | Ocaliva |
| Genentech USA, INC. | $31.37 | 2025 | Tecentriq |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.57 | 2019 | |
| Abbvie INC. | $17.93 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuko Kono listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.